Theravance Biopharma, Inc. (TBPH)
| Market Cap | 885.21M +27.4% |
| Revenue (ttm) | 104.31M +35.1% |
| Net Income | 53.81M +312.9% |
| EPS | 1.05 +300.8% |
| Shares Out | 51.92M |
| PE Ratio | 16.31 |
| Forward PE | 4.29 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 414,568 |
| Open | 17.04 |
| Previous Close | 17.04 |
| Day's Range | 17.03 - 17.06 |
| 52-Week Range | 13.08 - 21.03 |
| Beta | 0.25 |
| Analysts | Hold |
| Price Target | 17.67 (+3.64%) |
| Earnings Date | Aug 10, 2026 |
About TBPH
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. fo... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for TBPH stock is "Hold." The 12-month stock price target is $17.67, which is an increase of 3.64% from the latest price.
News
Theravance Biopharma Proxy statement: Proxy filing
Theravance Biopharma filed a proxy statement on August 25, 2026, providing details for shareholder voting and corporate governance matters.
Theravance Biopharma Proxy statement: Proxy filing
Theravance Biopharma filed a proxy statement on August 21, 2026, providing details for shareholder voting and corporate governance matters.
Theravance Biopharma Proxy statement: Proxy filing
Theravance Biopharma filed a proxy statement on August 11, 2026, providing details for shareholder voting and corporate governance matters.
Theravance Biopharma reports Q2 revenue $20.7M, consensus $22.32M
“During the second quarter, we entered into a definitive agreement to be acquired by Zymeworks, marking the culmination of a comprehensive strategic review process and what we believe achieves the…
Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Previously announced acquisition by Zymeworks expected to close in second half of 2026 YUPELRI ® Collaboration Revenue increased 11% year-over-year 1, from $18.7 million to $20.7 million, driven by co...
Theravance Biopharma Earnings release: Q2 2026
Theravance Biopharma released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Theravance Biopharma Quarterly report: Q2 2026
Theravance Biopharma has published its Q2 2026 quarterly earnings report on August 10, 2026.
Theravance Biopharma downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded Theravance Biopharma (TBPH) to Neutral from Buy with a $17 price target after the company announced an agreement to be acquired by Zymeworks (ZYME) for $17 per…
Zymeworks price target raised to $37 from $35 at Citi
Citi raised the firm’s price target on Zymeworks (ZYME) to $37 from $35 and keeps a Buy rating on the shares. The firm says the Theravance Biopharma (TBPH) acquisition adds…
Theravance Biopharma downgraded to Neutral from Buy at BTIG
BTIG downgraded Theravance Biopharma (TBPH) to Neutral from Buy after Zymeworks (ZYME) announced it has agreed to acquire the company for $17 per share. The firm does not anticipate any…
Theravance Biopharma downgraded to Hold from Buy at JonesResearch
JonesResearch analyst Debanjana Chatterjee downgraded Theravance Biopharma (TBPH) to Hold from Buy after Zymeworks (ZYME) announced it will acquire the company for $17.00 per share in cash. Published ...
Theravance Biopharma Proxy statement: Proxy filing
Theravance Biopharma filed a proxy statement on June 29, 2026, providing details for shareholder voting and corporate governance matters.
Why This Biotech Stock Is Falling After a $929 Million Buyout Lifeline
Theravance Biopharma strikes a deal with Zymeworks to be acquired for $17 a share.
M&A News: Biotech Group Zymeworks Buys Lung Disease-Fighting Peer Theravance for $1B
Shares in biotechnology company Zymeworks ($ZYME) were off color in pre-market trading today despite agreeing a near $1 billion deal to buy Theravance Biopharma ($TBPH). Cash Flows From Deal Vancouver...
Theravance Biopharma to be acquired by Zymeworks for $17.00 per share in cash
Theravance Biopharma (TBPH) announced that it has entered into a definitive agreement pursuant to which Zymeworks (ZYME) will acquire the company for $17.00 per share in cash, representing an equity…
Zymeworks strikes $929 million deal for Theravance Biopharma
Drugmaker Zymeworks said on Monday it will buy Theravance Biopharma in a $929 million deal.
Zymeworks to acquire Theravance Biopharma for $17.00 per share, or $929M
Zymeworks (ZYME) announced it has entered into a definitive agreement to acquire Theravance Biopharma (TBPH). This proposed acquisition adds YUPELRI, the first and only nebulized, once-daily, long-act...
Zymeworks to acquire Theravance Biopharma for $17.00 per share
06:00 EDT Zymeworks (ZYME) to acquire Theravance Biopharma (TBPH) for $17.00 per share
THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT
Theravance Biopharma shareholders to receive $17.00 per share in cash, representing an equity value of approximately $929 million Theravance Biopharma shareholders to receive a contingent value right ...
Theravance Biopharma reports Q1 EPS (10c) vs. (17c) last year
Reports Q1 revenue $17.7M, consensus $17.45M. “We delivered strong financial performance in the first quarter, reinforcing the quality of our commercial asset, our robust balance sheet and the importa...
Theravance Biopharma Earnings release: Q1 2026
Theravance Biopharma released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Theravance Biopharma Quarterly report: Q1 2026
Theravance Biopharma has published its Q1 2026 quarterly earnings report on May 7, 2026.
Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
YUPELRI ® Collaboration Revenue increased 15% year-over-year 1 , from $15.4 million to $17.7 million, driven by continued Net Sales growth and improved operating leverage All Hatch-Waxman litigation r...
Theravance Biopharma Proxy statement: Proxy filing
Theravance Biopharma filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Theravance Biopharma price target raised to $17 from $14 at B. Riley
B. Riley raised the firm’s price target on Theravance Biopharma (TBPH) to $17 from $14 and keeps a Neutral rating on the shares. The final generic settlement with Mankind (MNKD)…